Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06052670
Other study ID # 2023-GSP-GG-4
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 20, 2023
Est. completion date December 31, 2024

Study information

Verified date September 2023
Source China National Center for Cardiovascular Diseases
Contact Jie Qian, MD
Phone +8613601396650
Email qianjfw@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective, single-center study. The primary purpose of this study is to evaluate the sensitivity and specificity of offline computational ultrasonic flow ratio (UFR) with conventional pressure wire-based fractional flow reserve (FFR) as the standard reference. The study will be conducted in Fuwai Hospital, and a total of 408 patients with coronary vessel diameter stenosis ≥30% and ≤80% are planned to be recruited. Participants who meet the inclusion criteria and do not meet the exclusion criteria will undergo intravascular ultrasound (IVUS) followed by FFR examination. IVUS imaging will be sent to an independent core laboratory for UFR calculation. UFR analyses were performed offline in a blinded fashion without awareness of FFR measurement. Using FFR≤0.80 as the gold standard, the sensitivity and specificity of UFR in the functional significance of coronary artery stenosis will be analyzed.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 408
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Stable angina pectoris, unstable angina pectoris, or after the acute phase of myocardial infarction - Age =18 years - Written informed consent - Intermediated coronary lesions (diameter stenosis of 30%-80% by visual estimation from coronary angiography) Exclusion Criteria: - Ineligible for diagnostic IVUS or FFR examination - Prior coronary artery bypass grafting of the interrogated vessels - Myocardial infarction within 72 h of coronary angiography - Severe heart failure - Serum creatinine levels >150 umol/L, or glomerular filtration rates <45 ml/kg/1.73 m2 - Allergy to the contrast agent or adenosine - Life expectancy < 2 years - IVUS pullback not covering the entire lesion - Severe myocardial bridge in the interrogated vessel

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)
pressure wire-based fractional flow reserve (FFR); intravascular ultrasound (IVUS)-based ultrasonic flow ratio (UFR)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
China National Center for Cardiovascular Diseases

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity and specificity of UFR in predicting functionally significant coronary stenosis at the patient level, using FFR as the reference standard Sensitivity is defined as the proportion of UFR = 0.80 in patients with hemodynamically-significant stenosis as measured by FFR (FFR = 0.80); specificity is defined as the proportion of UFR > 0.80 in patients without hemodynamically-significant stenosis as measured by FFR (FFR > 0.80). Immediately after the procedure
Secondary Sensitivity and specificity of UFR in predicting functionally significant coronary stenosis at the vessel level, using FFR as the reference standard Sensitivity is defined as the proportion of UFR = 0.80 in vessels with hemodynamically-significant stenosis as measured by FFR (FFR = 0.80); specificity is defined as the proportion of UFR > 0.80 in vessels without hemodynamically-significant stenosis as measured by FFR (FFR > 0.8). Immediately after the procedure
Secondary Diagnostic accuracy of UFR in predicting functionally significant coronary stenosis at the patient level, using FFR as the reference standard Diagnostic accuracy is defined as UFFR (=0.80 or >0.80) to identify hemodynamically-significant coronary stenosis with FFR (=0.8 or >0.8) as the reference standard. Immediately after the procedure
Secondary The AUC of UFR for coronary stenosis with FFR as the gold standard AUC is defined as the area under the receiver-operating characteristic curve Immediately after the procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05133843 - Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Implantation (TAVI) in Patients With Severe Symptomatic Aortic Valve Stenosis N/A
Completed NCT01205776 - EXCEL Clinical Trial N/A
Completed NCT01332591 - Multivessel Disease Diagnosed at the Time of PPCI for STEMI: Complete Revascularization Versus Conservative Strategy. N/A
Completed NCT01182428 - XIENCE V: SPIRIT WOMEN Sub-study Phase 4
Completed NCT00739466 - Biorest Liposomal Alendronate With Stenting sTudy (BLAST) Phase 2
Completed NCT01310309 - EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease Phase 4
Completed NCT00531011 - EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease Phase 4
Completed NCT05509296 - Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease N/A
Not yet recruiting NCT05393882 - Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency
Recruiting NCT06397820 - Relation Between AI-QCA and Cardiac PET
Active, not recruiting NCT01960504 - First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II) N/A
Completed NCT01721096 - XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
Active, not recruiting NCT01342822 - Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization Phase 4
Completed NCT01205789 - EXCEL Clinical Trial (Universal Registry) N/A
Recruiting NCT05532605 - Effects of Mindfulness Based Therapy on Illness and Depression in Cardiac Rehab Phase-i N/A
Completed NCT02066623 - Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold
Not yet recruiting NCT02946320 - Optimal Predilatation Technique for BVS Implantation Phase 3
Completed NCT01249027 - XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
Terminated NCT01136915 - Kidney Damage In Patients With Severe Fall In eGFR Phase 4
Completed NCT01136876 - Kidney Damage in Patients With Moderate Fall in eGFR Phase 4